IP Library Granted Patent US 10,196,673
Granted Patent B2
US 10,196,673 · App. 14/768,871 · Granted Feb 5, 2019

Isolation of nucleic acids

Inventors: Koen Van Acker (Mechelen, BE); Bart Claes (Mechelen, BE); Benoit Devogelaere (Vilvoorde, BE); Geert Maertens (Mechelen, BE); Erwin Sablon (Mechelen, BE); Pascale Holemans (Mechelen, BE); Tania Ivens (Mechelen, BE)
Assignee: BIOCARTIS N.V.
C12Q1/6806C12Q1/686
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,196,673
App. No.
14/768,871
Granted
Feb 5, 2019
Kind
B2
Abstract

Improved compositions for and methods of processing and analyzing samples are described. In particular, the compositions and methods liberate nucleic acids from a biological sample allowing direct downstream processing of the nucleic acids in microfluidic systems. These compositions, methods and kits are useful in diagnosing, staging or otherwise characterizing various biological conditions.

Claims (29)

1. A method for releasing nucleic acids contained in a biological sample, the method comprising the step of:

contacting the biological sample with a composition for converting at least part of the sample into a lysate containing said nucleic acids, said lysate being directly transportable through a microfluidic system,

wherein the sample is a wax-embedded sample or a formalin fixation and paraffin embedding (FFPE) sample,

wherein the composition is a liquefaction composition that includes at least a non-ionic surfactant; and

performing a downstream analysis of a nucleic acid potentially present among the nucleic acids contained in the lysate,

wherein the downstream analysis

is performed within the microfluidic system,

comprises an amplification reaction of the nucleic acid, and

is a direct analysis of said nucleic acid, comprising providing at least a portion of the lysate containing the nucleic acids into the amplification reaction without purification of the nucleic acids from the non-ionic surfactant included in the liquefaction composition.

2. The method according to claim 1 wherein the amplification reaction comprises thermocycling.

3. The method according to claim 2 wherein the thermocycling comprises PCR.

4. A method according to claim 1 wherein the nucleic acid is DNA or RNA.

5. The method according to claim 1 wherein the non-ionic surfactant has the formula

R—O—(CH 2 CH 2 O) n H

wherein n>7; n≥8; or n=8;

and/or

R comprises 12≤C≤38.

6. The method according to claim 5 wherein R is CH 3 (CH 2 ) 7 —CH═CH—(CH 2 ) 8 or (CH 2 ) 10 —CH—(CH 3 ) 2 .

7. The method according to claim 5 wherein the non-ionic surfactant is (Z)-3,6,9,12,15,18,21,24-Octaoxadotetracont-33-en-1-ol.

8. A composition for releasing nucleic acid from and for liquefying a wax-embedded or an FFPE biological sample, said composition:

comprising at least a non-ionic surfactant, wherein the non-ionic surfactant is (Z)-3,6,9,12,15,18,21,24-Octaoxadotetracont-33-en-1-ol or polyethylene glycol monoalkyl ether that has the formula R—O—(CH 2 CH 2 O) n H wherein n=8; and

wherein the amount of the non-ionic surfactant is adapted such that when said composition is brought in contact with the biological sample, at least a part of the biological sample is converted into a lysate directly transportable through a microfluidic system, wherein the amount of the non-ionic surfactant in the composition is between 0.10% and 0.40%, said lysate at the same time being suitable for performing a direct analysis of the contained therein released nucleic acid by means of a nucleic acid amplification reaction, wherein said amplification reaction is performed in the presence of said lysate without prior purification of the released nucleic acid from the non-ionic surfactant.

9. A composition for releasing nucleic acid according to claim 8 wherein the non-ionic surfactant is (Z)-3,6,9,12,15,18,21,24-Octaoxadotetracont-33-en-1-ol.

10. A method according to claim 1 wherein the direct analysis comprises providing at least a portion of the lysate into the amplification reaction, wherein the lysate is undiluted or minimally diluted.

11. A method according to claim 3 wherein the PCR comprises real-time detection.

12. A composition for releasing nucleic acid according to claim 8 wherein said lysate is suitable for performing a direct analysis of the released nucleic acid while being undiluted or minimally diluted.

13. A composition for releasing nucleic acid according to claim 8 wherein said lysate is suitable for performing a direct analysis of the released nucleic acid while being diluted 2-fold.

14. The method according to claim 5 wherein the non-ionic surfactant is polyethylene glycol monoalkyl ether.

15. A composition for releasing nucleic acid according to claim 8 wherein the non-ionic surfactant is polyethylene glycol monoalkyl ether.

Assignments (4)
SECURITY INTEREST Recorded Oct 31, 2023
From: BIOCARTIS NV
To: GLAS TRUST CORPORATION LIMITED
Reel/Frame 065411/0175 →
SECURITY INTEREST Recorded Nov 4, 2022
From: BIOCARTIS NV
To: GLAS TRUST CORPORATION LIMITED
Reel/Frame 061657/0976 →
SECURITY INTEREST Recorded Oct 28, 2022
From: BIOCARTIS NV
To: GLAS TRUST CORPORATION LIMITED
Reel/Frame 061583/0397 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2015
From: VAN ACKER, KOEN; CLAES, BART; DEVOGELAERE, BENOIT; MAERTENS, GEERT; SABLON, ERWIN; HOLEMANS, PASCALE; IVENS, TANIA
To: BIOCARTIS N.V.
Reel/Frame 037103/0027 →
Priority Claims (1)
EP 13156609 · Feb 25, 2013 · regional
Continuity (1)
Related Publication 20160002706A1 · Jan 7, 2016